Moomoo AI 已提取核心信息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on March 11, 2024, that the U.S. Patent and Trademark Office (USPTO) has issued a new patent for Talicia, their all-in-one treatment for Helicobacter pylori (H. pylori) infection. The patent, which extends protection for Talicia until February 12, 2034, supports the company's existing intellectual property portfolio, including composition of matter patents and FDA-granted data exclusivities under the GAIN QIDP designation and section 505(b)(2). Talicia is the only FDA-approved therapy containing rifabutin for H. pylori eradication and is the leading branded first-line therapy prescribed by U.S. gastroenterologists. The infection affects approximately 35% of the U.S. adult population. The new patent is expected to bolster Talicia's market exclusivity and strengthen RedHill's commercial position. The announcement also highlighted Talicia's optimized antibiotic resistance profile and its pivotal Phase 3 study results, which showed an 84% eradication rate of H. pylori. RedHill Biopharma focuses on gastrointestinal and infectious diseases and promotes other gastrointestinal drugs alongside Talicia.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on March 11, 2024, that the U.S. Patent and Trademark Office (USPTO) has issued a new patent for Talicia, their all-in-one treatment for Helicobacter pylori (H. pylori) infection. The patent, which extends protection for Talicia until February 12, 2034, supports the company's existing intellectual property portfolio, including composition of matter patents and FDA-granted data exclusivities under the GAIN QIDP designation and section 505(b)(2). Talicia is the only FDA-approved therapy containing rifabutin for H. pylori eradication and is the leading branded first-line therapy prescribed by U.S. gastroenterologists. The infection affects approximately 35% of the U.S. adult population. The new patent is expected to bolster Talicia's market exclusivity and strengthen RedHill's commercial position. The announcement also highlighted Talicia's optimized antibiotic resistance profile and its pivotal Phase 3 study results, which showed an 84% eradication rate of H. pylori. RedHill Biopharma focuses on gastrointestinal and infectious diseases and promotes other gastrointestinal drugs alongside Talicia.
专业生物制药公司RedHill Biopharma Ltd. 于2024年3月11日宣布，美国专利商标局（USPTO）已为其治疗幽门螺杆菌（H. pylori）感染的多合一疗法塔利西亚颁发了一项新专利。该专利将对塔利西亚的保护延长至2034年2月12日，支持该公司现有的知识产权组合，包括在GAIN QIDP名称和第505（b）（2）条下授予的物质专利和美国食品药品管理局授予的数据专有权。塔利西亚是唯一一种经美国食品药品管理局批准的含有利福布汀的用于根除幽门螺杆菌的疗法，也是美国胃肠病学家开出的领先品牌一线疗法。该感染影响了大约35％的美国成年人口。预计这项新专利将增强塔利西亚的市场排他性并巩固RedHill的商业地位。该公告还强调了塔利西亚优化的抗生素耐药特征及其关键的3期研究结果，该结果显示幽门螺杆菌的根除率为84％。RedHill Biopharma专注于胃肠道和传染病，除塔利西亚外，还推广其他胃肠道药物。
专业生物制药公司RedHill Biopharma Ltd. 于2024年3月11日宣布，美国专利商标局（USPTO）已为其治疗幽门螺杆菌（H. pylori）感染的多合一疗法塔利西亚颁发了一项新专利。该专利将对塔利西亚的保护延长至2034年2月12日，支持该公司现有的知识产权组合，包括在GAIN QIDP名称和第505（b）（2）条下授予的物质专利和美国食品药品管理局授予的数据专有权。塔利西亚是唯一一种经美国食品药品管理局批准的含有利福布汀的用于根除幽门螺杆菌的疗法，也是美国胃肠病学家开出的领先品牌一线疗法。该感染影响了大约35％的美国成年人口。预计这项新专利将增强塔利西亚的市场排他性并巩固RedHill的商业地位。该公告还强调了塔利西亚优化的抗生素耐药特征及其关键的3期研究结果，该结果显示幽门螺杆菌的根除率为84％。RedHill Biopharma专注于胃肠道和传染病，除塔利西亚外，还推广其他胃肠道药物。
有用
没用